Search
for
Sort by
Research 19
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
- Journal of Population Therapeutics and Clinical Pharmacology
- Modern Management Approaches for Alopecia Areata
- Janus kinase inhibitors for alopecia areata: A narrative review
- COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
- Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy
- Alopecia areata: current concepts
- Genetic Insights into Acne, Androgenetic Alopecia, and Alopecia Areata: Implications for Mechanisms and Precision Dermatology
- Comparison of Efficacy of Oral Tofacitinib Versus Oral Minoxidil in Patients with Alopecia Areata
- Jak inhibitors in the treatment of alopecia areata - a literature review
- Alopecia Areata: Pathogenesis, current treatments, and future perspectives
- Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
- A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies